Cantor Fitzgerald set a $26.00 target price on NewLink Genetics Corporation (NASDAQ:NLNK) in a research note published on Friday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other brokerages have also weighed in on NLNK. Zacks Investment Research raised NewLink Genetics Corporation from a sell rating to a hold rating in a research report on Saturday. Jefferies Group LLC reiterated a hold rating and set a $7.00 price target on shares of NewLink Genetics Corporation in a report on Friday, July 14th. SunTrust Banks, Inc. upgraded NewLink Genetics Corporation from a hold rating to a buy rating and upped their price target for the stock from $12.00 to $30.00 in a report on Thursday, March 30th. Robert W. Baird downgraded NewLink Genetics Corporation from an outperform rating to a neutral rating and decreased their price target for the stock from $25.00 to $8.00 in a report on Thursday, June 8th. Finally, ValuEngine downgraded NewLink Genetics Corporation from a sell rating to a strong sell rating in a report on Friday, June 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $18.17.

NewLink Genetics Corporation (NASDAQ NLNK) opened at 7.22 on Friday. NewLink Genetics Corporation has a 52-week low of $5.90 and a 52-week high of $25.17. The firm’s market capitalization is $211.41 million. The firm’s 50-day moving average is $7.17 and its 200-day moving average is $13.91.

NewLink Genetics Corporation (NASDAQ:NLNK) last issued its quarterly earnings results on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.21. NewLink Genetics Corporation had a negative return on equity of 52.36% and a negative net margin of 161.94%. The firm had revenue of $10.37 million for the quarter, compared to analyst estimates of $2.65 million. On average, equities analysts expect that NewLink Genetics Corporation will post ($3.05) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece was reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/newlink-genetics-corporation-nasdaqnlnk-pt-set-at-26-00-by-cantor-fitzgerald/1464951.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in NLNK. Vanguard Group Inc. increased its position in shares of NewLink Genetics Corporation by 5.6% in the first quarter. Vanguard Group Inc. now owns 959,883 shares of the biotechnology company’s stock worth $23,134,000 after buying an additional 51,013 shares during the period. FMR LLC increased its position in shares of NewLink Genetics Corporation by 119.3% in the fourth quarter. FMR LLC now owns 904,856 shares of the biotechnology company’s stock worth $9,302,000 after buying an additional 492,330 shares during the period. State Street Corp increased its position in shares of NewLink Genetics Corporation by 5.7% in the fourth quarter. State Street Corp now owns 430,428 shares of the biotechnology company’s stock worth $4,422,000 after buying an additional 23,029 shares during the period. Columbus Circle Investors increased its position in shares of NewLink Genetics Corporation by 155.6% in the first quarter. Columbus Circle Investors now owns 343,041 shares of the biotechnology company’s stock worth $8,267,000 after buying an additional 208,816 shares during the period. Finally, Driehaus Capital Management LLC acquired a new position in shares of NewLink Genetics Corporation during the first quarter worth about $5,127,000. Hedge funds and other institutional investors own 51.25% of the company’s stock.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.